Form 4: INSMED CEO Lewis Exercises Options, Sells Shares

INSMED Inc.'s Chair and CEO, William Lewis, executed a series of option exercises and subsequent sales of common stock on March 19, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• William Lewis, Chair and CEO of INSMED Inc., engaged in transactions involving the company's common stock on March 19, 2026.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2025.
• Lewis exercised options to acquire 6,259 shares of common stock at an exercise price of $30.46 per share.
• He also exercised options to acquire an additional 4,440 shares of common stock at an exercise price of $17.16 per share.
• Following the option exercises, Lewis sold 1,629 shares of common stock at a weighted average price of $142.17 per share, with prices ranging from $141.80 to $142.74.
• An additional 4,537 shares were sold at a weighted average price of $143.42 per share, with prices ranging from $142.80 to $143.77.
• A further 4,533 shares were sold at a weighted average price of $144.11 per share, with prices ranging from $143.80 to $144.72.
• After these reported transactions, Lewis directly beneficially owns 301,185 shares of common stock.
• He also indirectly beneficially owns 233,924 shares of common stock through the Katie Procter Dynasty Trust.
• Lewis retains 50,073 unexercised stock options with an exercise price of $30.46 and 35,520 unexercised stock options with an exercise price of $17.16.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event, typical for executive compensation and personal financial planning, with the sales executed at a significant profit over the exercise prices.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and systematic approach to managing personal holdings rather than reactive selling.
• The sale prices for the common stock ($142.17, $143.42, $144.11) are significantly higher than the option exercise prices ($30.46, $17.16), indicating a profitable transaction for the insider.

Negatives

• Insider selling, even when conducted under a 10b5-1 plan, can sometimes be perceived by the market as a reduction in the insider's direct equity stake, though this is a routine event for executives.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales under 10b5-1 plans, are common practice for executives to manage personal finances and diversify holdings without implying a negative outlook on the company's future. These transactions are generally pre-scheduled to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO, while routine under a 10b5-1 plan, may lead to minor market speculation. However, the overall impact on the company's operational or strategic direction is minimal.

Key Dates

Recommendation

The filing details routine insider transactions under a pre-arranged 10b5-1 plan, which are common for executives managing personal finances. While there is insider selling, it does not suggest a change in the company's fundamentals or a negative outlook. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to warrant a change in investment thesis.

Keywords

INSMED Inc., INSM, Form 4, Insider Trading, Stock Options, Equity Sales, William Lewis, CEO, Director, 10b5-1 Plan